Category Archives: Darvocet and Darvon

Subscribe to Darvocet and Darvon RSS Feed

FDA Considers Change in Labeling Requirements for Generic Manufacturers

Posted in Darvocet and Darvon, Defective Drugs

According to recent reports, the FDA is considering new labeling requirements for the manufacturers of generic drugs, which could lead to a change in a company’s responsibility to consumers. Currently, generic manufacturers are required by federal law to have the same labels as the branded version. As a result of this federal law, the United… Continue Reading

Additional Defendants Dismissed from Darvocet Litigation

Posted in Darvocet and Darvon, Defective Drugs

On April 18, 2012, Judge Danny Reeves, who is overseeing all federal Darvocet cases centralized in Kentucky, dismissed defendants, Endo Pharmaceuticals Holdings, Inc. and Endo Pharmaceuticals, Inc. (“Endo Defendants”), from the litigation because the Court lacks specific or general jurisdiction over them. On approximately December 1, 2010, just eleven days after the propoxyphene products were… Continue Reading

Democrats Endorse Bill in Congress to Hold Generic Drugmakers Liable

Posted in Darvocet and Darvon, Defective Drugs

Bills were just recently introduced in the US House of Representatives and the US Senate which would effectively overrule the Supreme Court’s decision 2011 decision in Pliva v. Mensing by “allow[ing] generic drug companies to be held liable under state tort law for failing to update warning labels with known dangers.” In a 5-4 split,… Continue Reading

Stark & Stark Shareholder Comments on Status of Darvocet & Darvon Litigation

Posted in Darvocet and Darvon, Defective Drugs

Kevin M. Hart, Chair of Stark & Stark’s Mass Tort Litigation Group, was quoted in the January 25, 2012 New Jersey Law Journal article, Suits Allege Lilly Failed To Warn of Darvocet’s and Darvon’s Health Risks. The article discusses a recent case in which former Darvocet and Darvon users are claiming that the manufacturer of… Continue Reading

Multi-District Litigation Granted in Darvocet Litigation

Posted in Darvocet and Darvon, Defective Drugs

As we previously reported, the United States Judicial Panel on Multi-District Litigation (MDL) met in March 2011, in San Diego, CA, to hear arguments regarding whether the Darvocet and Darvon cases should be given MDL treatment. In April 2011, the Panel announced that it needed more time to consider the arguments for and against consolidating the federal cases. As such, the Panel scheduled an additional hearing for July 2011, in San Francisco, CA, to consider further arguments.

Panel Scheduled to Meet Again to Consider MDL Treatment in Darvocet Cases

Posted in Darvocet and Darvon, Defective Drugs

The United States Judicial Panel on Multi-District Litigation (MDL) is scheduled to meet on July 28, 2011, in San Francisco, CA to hear further argument on whether all federal Darvocet and Darvon cases should be centralized, pursuant to 28 U.S.C.§ 1407, for coordinated or consolidated pretrial proceedings, and if so, which federal district is the appropriate forum for these proceedings.

Should Darvocet Cases Be Given MDL Treatment?

Posted in Darvocet and Darvon, Defective Drugs

As we previously reported, the United States Judicial Panel on Multi-District Litigation (MDL) met on Wednesday, March 30, 2011, in San Diego, CA, to hear arguments regarding whether the Darvocet and Darvon federal cases should be given MDL treatment. One of the main sources of contention among the parties is where to centralize the cases. The proposed locations include: the Eastern District of New York, the Northern District of Illinois, the Eastern District of Louisiana, the Western District of Louisiana, the Southern District of Ohio and the Eastern District of Kentucky.

Still Waiting on MDL Decision in Darvocet Cases

Posted in Darvocet and Darvon, Defective Drugs

As we have previously reported, in November, 2010, the FDA finally announced that it was pulling off the U.S. market the prescription painkillers, Darvon and Darvocet, which combines Darvon with the aspirin substitute acetaminophen, because of scientific evidence the drugs can damage the heart, even at recommended doses, or cause fatal cardiac abnormalities. Studies have shown that the ingredients contained in Darvocet and Darvon have been linked to various forms of severe side-effects. Reportedly, these side-effects include: heart arrhythmia, heart attack, suicide, overdose and even death.